UNSPSC 51111786: Pembrolizumab

Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.

UNSPSC 51111786 Pembrolizumab is a Commodity code that nominally covers a single immunotherapy pharmaceutical product, but the recent state and local opportunities tagged under this code show no relevant procurement activity for pembrolizumab itself. The opportunities in the dataset instead span unrelated goods and services—medical oxygen rentals, naloxone and drug deactivation systems, generic pharmaceuticals and OTC products through cooperative purchasing, and various county procurement forums and educational events—none of which involve pembrolizumab or targeted cancer therapy drugs. The code appears to be either misapplied across these opportunities or inactive for its intended scope in recent state and local solicitations.

No state or local jurisdiction has posted a solicitation specifically for pembrolizumab or similar monoclonal antibody immunotherapy drugs under this code in the available recent opportunities. The geographic spread of unrelated postings includes Texas (Williamson County), Florida (Seminole County, Pinellas County, Marion County, Collier County, Indian River County, Pasco County), Arizona (Tucson), Arkansas (Little Rock), Minnesota (MMCAP, multistate), and California (San Mateo County), but these represent purchasing activity in other UNSPSC categories, not pembrolizumab procurement. Until state and local health systems, pharmacy benefit programs, hospital networks, or oncology-focused purchasing groups post formal solicitations specifically for pembrolizumab supply, pricing, or distribution under this or a related pharmaceutical code, activity under 51111786 remains dormant for business development purposes.